ePrints

Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series

Lookup NU author(s): Dr Vickyanne Carruthers, Dr Shelby BarnettORCiD, Dr Tasnim Arif, Professor Gareth Veal

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC. Infantile myofibroma is a rare, benign tumour of infancy typically managed surgically. In a minority of cases, more aggressive disease is seen and chemotherapy with vinblastine and methotrexate may be used, although evidence for this is limited. Chemotherapy dosing in infants is challenging, and vinblastine disposition in infants is unknown. We describe the use of vinblastine therapeutic drug monitoring in four cases of infantile myofibroma. Marked inter- and intrapatient variability was observed, highlighting the poorly understood pharmacokinetics of vinblastine in children, the challenges inherent in treating neonates, and the role of adaptive dosing in optimising drug exposure in challenging situations.

Publication metadata

Author(s): Carruthers V, Barnett S, Rees R, Arif T, Slater O, Ramanujachar R, Johnson K, Brown S, Graham C, Burke GAA, Veal GJ

Publication type: Article

Publication status: Published

Journal: Pediatric Blood and Cancer

Year: 2022

Volume: 69

Issue: 7

Pages: e29722

Print publication date: 01/07/2022

Online publication date: 20/04/2022

Acceptance date: 15/03/2022

Date deposited: 17/05/2022

ISSN (print): 1545-5009

ISSN (electronic): 1545-5017

Publisher: John Wiley and Sons Inc.

URL: https://doi.org/10.1002/pbc.29722

DOI: 10.1002/pbc.29722

PubMed id: 35441483

Altmetrics

Funding

Share